Related Experiment Video
Updated: Aug 17, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
[Disseminated fusarium infection in two neutropenic children]
A Petit1, M D Tabone, D Moissenet
1Service d'hématologie et d'oncologie pédiatrique, hôpital d'enfants Armand-Trousseau, Assistance-publique-Hôpitaux de Paris, France.
Insights
Disseminated fusariosis is a severe fungal infection in children. Voriconazole shows promise as an alternative treatment to amphotericin B for this rare condition.
Area of Science:
- Mycology
- Pediatric Oncology
- Infectious Diseases
Background:
- Disseminated fusariosis is a rare, life-threatening fungal infection primarily affecting immunocompromised children, particularly those with hematologic malignancies or post-bone marrow transplant.
- Treatment challenges and high mortality rates (50-70% in adults) underscore the need for effective therapeutic strategies.
Observation:
- Two pediatric cases of disseminated fusariosis are presented: one fatal case in a boy with relapsed acute lymphoblastic leukemia despite amphotericin B treatment.
- A second case in a girl with acute myeloid leukemia showed treatment failure with amphotericin B but achieved recovery with voriconazole and resolution of neutropenia.
Findings:
- Voriconazole demonstrated efficacy in a pediatric case of disseminated fusariosis unresponsive to amphotericin B.
- The patient receiving voriconazole experienced disease remission and tolerated secondary prophylaxis during subsequent leukemia relapse treatment.
Implications:
- Voriconazole represents a potential alternative antifungal agent for managing disseminated fusariosis in pediatric patients.
- Its use, both for acute treatment and secondary prophylaxis, warrants further investigation in this vulnerable population.
Unlabelled:
Disseminated fusariosis in children is a rare and serious fungal infection, that occurs especially in neutropenic immunosuppressed patients, treated for malignant hemopathy, or bone marrow transplant recipient. Treatment is difficult and mortality is estimated between 50 and 70% in adult patients. CASE REPORT 1: A ten-year-old boy, treated for an acute lymphoblastic leukemia in second relapse, presented a disseminated fusarium spp infection, that occurred during neutropenia. He died due to fusariosis infection in spite of amphotericin B treatment. CASE REPORT 2: A ten-year-old neutropenic girl, treated for an acute myeloïd leukemia, presented disseminated fusariosis, uncontrolled by amphotericin B. Recovery was observed after voriconazole introduction and resolution of neutropenia. Ten months later, she presented a leukemia's relapse, treated by new intensive chemotherapy with secondary prophylaxis by voriconazole, without fusariosis's recurrence.
Conclusion:
Voriconazole, a new triazole agent, seems to be an alternative antifungal agent to amphotericin B for disseminated fusarium infection, either at the acute phase or for secondary prophylaxis.
Related Concept Videos
Cryptococcal Meningitis
Fungal Phylum Microsporidia
Rocky Mountain Spotted Fever
